The pharmaceutical company Daiichi Sankyo has chosen the North as the next target for its global expansion, and the Danish capital will become the base for the Nordic advancement.
Daiichi Sakyo has hired German Patrik Grandits to lead to Nordic division. He is also head of the company's European cancer division.
Daiichi Sakyo is already represented in 20 countries, and employs more than 15,000 people, 2,000 of which are employed in the 12 local European Departments. The Danish subsidiary, which has been named Daiichi Sankyo Oncology Nordics, will be situated in the Copenhagen Bio Science Park - also known as COBIS. And from the offices there, the company will open smaller divisions i Sweden, Norway, Finland and the Baltic countries.
The decision to place the Nordic headquarters in Copenhagen followed a great deal of lobbying work from the organization Copenhagen Capacity, which is known for marketing the metropolitan region Greater Copenhagen, the region around eastern Denmark and southern Sweden, as an opportunity for finding collaborative partners among the 12 universities, 32 hospitals and more than 300 biotech companies that form the life science cluster Medicon Valley.
"Daiichi Sankyo will both strengthen the cluster's ecosystem - just as the company will contribute with new knowledge and insight that can do something for Denmark's already strong position in cancer research," says Claus Lønborg, Managing Director and CEO of Copenhagen Capacity.
In 2018 and 2019, Copenhagen Capacity and Greater Copenhagen will accentuate the region as a life science hub, and will work towards recruiting international labor, companies and capital for the region within the sector.
English Edit: Ida Jacobsen
Would you like to receive the latest news from MedWatch directly in your e-mail inbox? Sign up for our free English newsletter below.